Axitinib
- Generic Name
- Axitinib
- Brand Names
- Inlyta, Axitinib Accord
- Drug Type
- Small Molecule
- Chemical Formula
- C22H18N4OS
- CAS Number
- 319460-85-0
- Unique Ingredient Identifier
- C9LVQ0YUXG
- Background
Axitinib is a second generation tyrosine kinase inhibitor that works by selectively inhibiting vascular endothelial growth factor receptors (VEGFR-1, VEGFR-2, VEGFR-3). Through this mechanism of action, axitinib blocks angiogenesis, tumour growth and metastases. It is reported to exhibit potency that is 50-450 times higher than that of the first generation V...
- Indication
Used in kidney cell cancer and investigated for use/treatment in pancreatic and thyroid cancer.
- Associated Conditions
- Advanced Renal Cell Carcinoma, Advanced Thyroid cancer
- Associated Therapies
- First Line Chemotherapy
A Study of Immune Checkpoint Inhibitor Combinations With Axitinib in Participants With Untreated Locally Advanced Unresectable or Metastatic Renal Cell Carcinoma
- Conditions
- Interventions
- First Posted Date
- 2023-04-10
- Last Posted Date
- 2024-10-24
- Lead Sponsor
- Hoffmann-La Roche
- Target Recruit Count
- 210
- Registration Number
- NCT05805501
- Locations
- 🇺🇸
Vanderbilt University Medical Center; Vanderbilt University, Nashville, Tennessee, United States
🇺🇸EMORY UNIVERSITY; Bone Marrow & Stem Cell Transplant Center, Atlanta, Georgia, United States
🇺🇸SCRI Oncology Partners, Nashville, Tennessee, United States
Postoperative Adjuvant Therapy for Non-clear Renal Cell Carcinoma With High-risk Recurrence Factors
- Conditions
- Interventions
- First Posted Date
- 2023-03-14
- Last Posted Date
- 2023-03-14
- Target Recruit Count
- 30
- Registration Number
- NCT05768464
- Locations
- 🇨🇳
Department of Urology, Drum Tower Hospital, Medical School of Nanjing University, Institute of Urology, Nanjing University, Nanjing, Jiangsu, China
🇨🇳Hongqian Guo, Nanning, Jiangsu, China
Treatment Outcomes in Japanese RCC Patients Treated With Avelumab Plus Axitinib as First-line Therapy: Retrospective Study (J-DART2)
- First Posted Date
- 2022-12-14
- Last Posted Date
- 2024-01-11
- Lead Sponsor
- Merck Healthcare KGaA, Darmstadt, Germany, an affiliate of Merck KGaA, Darmstadt, Germany
- Target Recruit Count
- 171
- Registration Number
- NCT05650164
- Locations
- 🇯🇵
Osaka University Hospital, Suita-city, Osaka, Japan
🇯🇵Hiroshima University Hospital, Hiroshima, Japan
🇯🇵Kindai University Hospital, Osakasayama, Osaka, Japan
An Observational Chart Review Study To Describe The Real-World Outcomes And Use Of Avelumab In Combination With Axitinib For Treatment Of Patients With aRCC In The UK
- First Posted Date
- 2022-05-27
- Last Posted Date
- 2023-12-06
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 130
- Registration Number
- NCT05394493
- Locations
- 🇬🇧
Pfizer Ltd, Sandwich, Kent, United Kingdom
Axitinib and Nivolumab for the Treatment of Mucosal Melanoma
- Conditions
- Interventions
- First Posted Date
- 2022-05-20
- Last Posted Date
- 2024-02-23
- Lead Sponsor
- Memorial Sloan Kettering Cancer Center
- Target Recruit Count
- 20
- Registration Number
- NCT05384496
- Locations
- 🇺🇸
Memorial Sloan Kettering Westchester, Harrison, New York, United States
🇺🇸Memorial Sloan Kettering Cancer Center, New York, New York, United States
Seleno-L Methionine (SLM)-Axitinib-Pembrolizumab
- Conditions
- Interventions
- First Posted Date
- 2022-05-06
- Last Posted Date
- 2024-12-17
- Lead Sponsor
- Bilal G. Rahim
- Target Recruit Count
- 55
- Registration Number
- NCT05363631
- Locations
- 🇺🇸
University of Iowa Hospitals & Clinics, Iowa City, Iowa, United States
Testing the Addition of Stereotactic Radiation Therapy With Immune Therapy for the Treatment of Patients With Unresectable or Metastatic Renal Cell Cancer, SAMURAI Study
- Conditions
- Interventions
- First Posted Date
- 2022-04-14
- Last Posted Date
- 2024-03-12
- Lead Sponsor
- NRG Oncology
- Target Recruit Count
- 240
- Registration Number
- NCT05327686
- Locations
- 🇺🇸
University of Maryland/Greenebaum Cancer Center, Baltimore, Maryland, United States
🇺🇸Dayton Physicians LLC-Atrium, Franklin, Ohio, United States
🇺🇸Miami Valley Cancer Care and Infusion, Greenville, Ohio, United States
Optimizing Pembrolizumab Therapy With Timing and Intensification With Axitinib
- First Posted Date
- 2022-03-02
- Last Posted Date
- 2022-08-02
- Lead Sponsor
- University of Oklahoma
- Registration Number
- NCT05263609
A Study of AK104 Monotherapy or AK104 Plus Axitinib in Advanced/Metastatic Renal Cell Carcinoma
- Conditions
- Interventions
- First Posted Date
- 2022-02-25
- Last Posted Date
- 2023-09-21
- Lead Sponsor
- Akeso
- Target Recruit Count
- 70
- Registration Number
- NCT05256472
- Locations
- 🇨🇳
Fudan University Shanghai Cancer Center, Shanghai, Shanghai, China
Study of Bavituximab, Axitinib, and Avelumab in Advanced Hepatocellular Carcinoma
- Conditions
- Interventions
- First Posted Date
- 2022-02-21
- Last Posted Date
- 2023-05-03
- Lead Sponsor
- University of Texas Southwestern Medical Center
- Target Recruit Count
- 1
- Registration Number
- NCT05249569
- Locations
- 🇺🇸
The University of Texas Southwestern Medical Center, Dallas, Texas, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.